Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

ABBOTT LABORATORIES

(ABT)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
11/05/2019 11/06/2019 11/07/2019 11/08/2019 11/11/2019 Date
82.34(c) 83.12(c) 83.39(c) 83.74(c) 83.76(c) Last
8 238 802 4 489 005 6 020 547 3 462 833 3 139 074 Volume
+0.15% +0.95% +0.32% +0.42% +0.02% Change
More quotes
Financials (USD)
Sales 2019 31 851 M
EBIT 2019 7 153 M
Net income 2019 3 655 M
Debt 2019 13 029 M
Yield 2019 1,52%
Sales 2020 33 940 M
EBIT 2020 7 895 M
Net income 2020 4 487 M
Debt 2020 5 641 M
Yield 2020 1,64%
P/E ratio 2019 39,7x
P/E ratio 2020 32,9x
EV / Sales2019 5,02x
EV / Sales2020 4,50x
Capitalization 147 B
More Financials
Company
Abbott Laboratories specializes in the research, development, manufacturing and marketing of pharmaceutical and medical products. Net sales break down by family of products as follows: - vascular devices (30.9%): endoprosthetic systems, dilation catheters, arterial closures, etc.; - diagnostic... 
More about the company
Surperformance© ratings of Abbott Laboratories
Trading Rating : Investor Rating :
More Ratings
Latest news on ABBOTT LABORATORIES
06:20aABBOTT LABORATORIES : Other Events (form 8-K)
AQ
11/11Corporate Briefing Session of Abbott Laboratories Limited
AQ
11/06ABBOTT : Announces Discovery of New Strain of HIV, Keeping Global Health Communi..
PR
10/31ABBOTT LABORATORIES : Management's Discussion and Analysis of Financial Conditio..
AQ
10/30Transmission of Quarterly Report for the Period Ended September 30, 2019 of A..
AQ
10/21ABBOTT LABORATORIES : The Australian Red Cross Blood Service Selects Abbott's Al..
PR
10/18Financial results of Abbott Laboratories Limited for Quarter ended September ..
AQ
10/17Exchange Rates Deal $22.56 Billion Blow to Companies' Earnings
DJ
10/16Abbott revenue misses as heart devices eclipse diabetes gains
RE
10/16ABBOTT LABORATORIES : - canadians indicate growing concern about road safety at ..
AQ
10/16Stocks to Watch: Netflix, AmerisourceBergen, Bank of America, Yum, Abbott Lab..
DJ
10/16ABBOTT LABORATORIES : Tweaks 2019 Profit Outlook
DJ
10/16ABBOTT LABORATORIES : 3Q Sales Slightly Lower Than Wall Street Targets
DJ
10/16ABBOTT : 3Q Earnings Snapshot
AQ
10/16ABBOTT LABORATORIES : Results of Operations and Financial Condition, Financial S..
AQ
More news
News in other languages on ABBOTT LABORATORIES
10/29AVIS D'ANALYSTES DU JOUR : Capgemini, Dassault Aviation, Engie, LVMH, Ubisoft, E..
10/29STOCK MARKET PARIS : Les cycliques tirent les indices vers le haut
10/24AVIS D'ANALYSTES DU JOUR : Carrefour, Ingenico, Peugeot, Worldline, Rémy Cointre..
10/24STOCK MARKET PARIS : "Super Mario" tire sa révérence
10/23STOCK MARKET PARIS : Moral en baisse avec le Brexit et Texas Instruments
More news
Analyst Recommendations on ABBOTT LABORATORIES
More recommendations
Sector news : Medical Equipment
11/07Cardinal Health Posts 1Q Loss, Driven by Litigation Charges
DJ
11/05ZIMMER BIOMET : Third-Quarter Sales, Profit Beat Street Views
DJ
11/05GLOBAL MARKETS LIVE : ArcelorMittal, Adecco, Pandora, Samsung…
11/05BECTON DICKINSON AND : Swung to Profit in 4Q
DJ
11/04WRIGHT MEDICAL N : Shares Surge on Takeover by Stryker
DJ
More sector news : Medical Equipment
Chart ABBOTT LABORATORIES
Duration : Period :
Abbott Laboratories Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 21
Average target price 93,39  $
Last Close Price 83,12  $
Spread / Highest target 32,3%
Spread / Average Target 12,4%
Spread / Lowest Target -15,8%
EPS Revisions
Managers
NameTitle
Miles D. White Chairman & Chief Executive Officer
Robert B. Ford President & Chief Operating Officer
Brian Bernard Yoor Chief Financial Officer & Executive VP-Finance
Roxanne Schuh Austin Independent Director
Samuel C. Scott Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ABBOTT LABORATORIES15.80%146 994
NOVOCURE LIMITED135.96%7 639
MASIMO CORPORATION34.79%7 509
ASAHI INTECC CO., LTD.-30.93%7 157
PENUMBRA, INC.37.63%5 777
GETINGE111.76%4 653